Tralokinumab治疗青少年中重度特应性皮炎的3期ECZTRA 6随机临床试验
ECZTRA 6是一项52周、随机、双盲、安慰剂对照的3期试验,在10个国家72个中心纳入12-17岁中重度特应性皮炎患者。第16周时,tralokinumab 150 mg和300 mg组达到IGA 0/1及EASI 75的比例均显著高于安慰剂组,且耐受性良好,疗效在52周内维持。
要点
- 第16周IGA 0/1(无急救药)比例:tralokinumab 150 mg组21.4%、300 mg组17.5%,安慰剂组4.3%,差异显著。
- 第16周EASI 75(无急救药)比例:tralokinumab 150 mg组28.6%、300 mg组27.8%,安慰剂组6.4%,差异显著。
- 第52周时,第16周达到主要终点的患者中超过50%在无急救药下维持疗效;tralokinumab耐受性良好。
核心结论
- Tralokinumab在青少年中重度特应性皮炎中有效且耐受性良好,支持其治疗价值。
研究设计与样本
- 52周、随机、双盲、安慰剂对照的3期ECZTRA 6试验,于2018年7月17日至2021年3月16日在北美、欧洲、亚洲和澳大利亚的10个国家72个中心开展。
- 纳入12-17岁中重度特应性皮炎患者(IGA评分≥3;EASI≥16),随机(1:1:1)接受tralokinumab 150 mg或300 mg或安慰剂每2周一次治疗16周,共301例随机,289例纳入全分析集(中位[IQR]年龄15.0[13.0-16.0]岁;149例[51.6%]男性)。
主要发现
- 第16周达到IGA 0/1(无急救药)比例:tralokinumab 150 mg组(n=98)21例(21.4%),300 mg组(n=97)17例(17.5%),安慰剂组(n=94)4例(4.3%);校正差异分别为17.5%(95%CI 8.4%-26.6%;P<.001)和13.8%(95%CI 5.3%-22.3%;P=.002)。
- 第16周达到EASI 75(无急救药)比例:tralokinumab 150 mg组28例(28.6%),300 mg组27例(27.8%),安慰剂组6例(6.4%);校正差异分别为22.5%(95%CI 12.4%-32.6%;P<.001)和22.0%(95%CI 12.0%-32.0%;P<.001)。
- 第16周青少年最严重瘙痒NRS较基线降低≥4分的比例:tralokinumab 150 mg组23.2%,300 mg组25.0%,安慰剂组3.3%。
- 第16周SCORAD较基线校正平均变化:tralokinumab 150 mg组-27.5,300 mg组-29.1,安慰剂组-9.5;CDLQI较基线校正平均变化:tralokinumab 150 mg组-6.1,300 mg组-6.7,安慰剂组-4.1。
- 第52周时,第16周达到主要终点的患者中超过50%在无急救药下维持疗效;开放标签阶段第52周IGA 0/1和EASI 75达标率分别为33.3%和57.8%。
关键数值与推荐
- 主要终点为第16周IGA评分0或1和/或达到EASI 75。
- 关键次要终点包括青少年最严重瘙痒NRS降低≥4分、SCORAD变化和CDLQI变化(从基线至第16周)。
- 安全性终点为不良事件和严重不良事件的数量;tralokinumab耐受性良好,截至第52周结膜炎频率未增加。
临床怎么用
- 原文结论认为tralokinumab有效且耐受性良好,支持其用于治疗青少年中重度特应性皮炎。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Safe and effective long-term treatments for adolescents with moderate to severe atopic dermatitis (AD) are limited. OBJECTIVE: To evaluate the efficacy and safety of interleukin-13-targeted treatment with tralokinumab monotherapy in adolescents with AD. DESIGN, SETTING, AND PARTICIPANTS: The 52-week, randomized, double-blinded, placebo-controlled, phase 3 ECZTRA 6 trial was conducted from July 17, 2018, through March 16, 2021, at 72 centers across 10 countries in North America, Europe, Asia, and Australia. Enrolled patients were 12 to 17 years old with moderate to severe AD (Investigator's Global Assessment [IGA] score ≥3; Eczema Area and Severity Index [EASI] ≥16). INTERVENTIONS: Patients were randomized (1:1:1) to tralokinumab (150 or 300 mg) or placebo every 2 weeks for 16 weeks. Patients with an IGA score of 0 (clear) or 1 (almost clear) and/or 75% or higher improvement in EASI (EASI 75) at week 16 without rescue medication received maintenance treatment; other patients switched to open-label tralokinumab, 300 mg, every 2 weeks. MAIN OUTCOMES AND MEASURES: Primary end points at week 16 were an IGA score of 0 or 1 and/or achieving EASI 75. Key secondary end points were a reduction of Adolescent Worst Pruritus Numeric Rating Scale of 4 or more, change in SCORing AD, and change in Children's Dermatology Life Quality Index from baseline to week 16. Safety end points were the number of adverse events and serious adverse events. RESULTS: Of 301 patients randomized, 289 comprised the full analysis set (median [IQR] age, 15.0 [13.0-16.0] years; 149 [51.6%] male). More patients receiving tralokinumab, 150 mg, (n = 98), and tralokinumab, 300 mg (n = 97), achieved an IGA score of 0 or 1 without rescue medication at week 16 (21 [21.4%] and 17 [17.5%], respectively) vs placebo (n = 94; 4 [4.3%]) (adjusted difference, 17.5% [95% CI, 8.4%-26.6%]; P < .001 and 13.8% [95% CI, 5.3%-22.3%]; P = .002, respectively). More patients receiving tralokinumab, 150 mg (28 [28.6%]), and tralokinumab, 300 mg, (27 [27.8%]) vs placebo (6 [6.4%]) achieved EASI 75 without rescue at week 16 (adjusted difference, 22.5% [95% CI, 12.4%-32.6%]; P < .001 and 22.0% [95% CI, 12.0%-32.0%]; P < .001, respectively). Proportions of patients with Adolescent Worst Pruritus Numeric Rating Scale reduction of 4 or more from baseline were greater with tralokinumab, 150 mg (23.2%), and tralokinumab, 300 (25.0%), vs placebo (3.3%), and adjusted mean changes were greater in SCORing AD with tralokinumab, 150 mg (-27.5), and tralokinumab, 300 mg (-29.1), vs placebo (-9.5) and in Children's Dermatology Life Quality Index with tralokinumab, 150 mg (-6.1), and tralokinumab, 300 mg (-6.7), vs placebo (-4.1) at week 16. At week 52, tralokinumab efficacy was maintained without rescue in more than 50% of patients meeting primary end point(s) at week 16. In the open-label phase, IGA score of 0 or 1 and EASI 75 were achieved in 33.3% and 57.8%, respectively, at week 52. Tralokinumab was well tolerated, without frequency of conjunctivitis increasing through week 52. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, tralokinumab was efficacious and well tolerated, supporting its value for treating adolescents with moderate to severe AD. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03526861.
引用
- Paller AS, Flohr C, Cork M, et al. Efficacy and Safety of Tralokinumab in Adolescents With Moderate to Severe Atopic Dermatitis: The Phase 3 ECZTRA 6 Randomized Clinical Trial. JAMA Dermatol. 2023. PMID: 37074705. doi:10.1001/jamadermatol.2023.0627
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。